IBDEI14F ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18185,0)
 ;;=E11.620^^61^805^5
 ;;^UTILITY(U,$J,358.3,18185,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18185,1,3,0)
 ;;=3^DM Type 2 w/ Diab Dermatitis
 ;;^UTILITY(U,$J,358.3,18185,1,4,0)
 ;;=4^E11.620
 ;;^UTILITY(U,$J,358.3,18185,2)
 ;;=^5002655
 ;;^UTILITY(U,$J,358.3,18186,0)
 ;;=E11.36^^61^805^4
 ;;^UTILITY(U,$J,358.3,18186,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18186,1,3,0)
 ;;=3^DM Type 2 w/ Diab Cataract
 ;;^UTILITY(U,$J,358.3,18186,1,4,0)
 ;;=4^E11.36
 ;;^UTILITY(U,$J,358.3,18186,2)
 ;;=^5002642
 ;;^UTILITY(U,$J,358.3,18187,0)
 ;;=I10.^^61^806^1
 ;;^UTILITY(U,$J,358.3,18187,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18187,1,3,0)
 ;;=3^Essential/Primary Hypertension
 ;;^UTILITY(U,$J,358.3,18187,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,18187,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,18188,0)
 ;;=I11.0^^61^806^12
 ;;^UTILITY(U,$J,358.3,18188,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18188,1,3,0)
 ;;=3^Hypertensive Heart Disease w/ Heart Failure
 ;;^UTILITY(U,$J,358.3,18188,1,4,0)
 ;;=4^I11.0
 ;;^UTILITY(U,$J,358.3,18188,2)
 ;;=^5007063
 ;;^UTILITY(U,$J,358.3,18189,0)
 ;;=I11.9^^61^806^13
 ;;^UTILITY(U,$J,358.3,18189,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18189,1,3,0)
 ;;=3^Hypertensive Heart Disease w/o Heart Failure
 ;;^UTILITY(U,$J,358.3,18189,1,4,0)
 ;;=4^I11.9
 ;;^UTILITY(U,$J,358.3,18189,2)
 ;;=^5007064
 ;;^UTILITY(U,$J,358.3,18190,0)
 ;;=I12.0^^61^806^5
 ;;^UTILITY(U,$J,358.3,18190,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18190,1,3,0)
 ;;=3^Hypertensive CKD w/ Stage 5 CKD or ESRD
 ;;^UTILITY(U,$J,358.3,18190,1,4,0)
 ;;=4^I12.0
 ;;^UTILITY(U,$J,358.3,18190,2)
 ;;=^5007065
 ;;^UTILITY(U,$J,358.3,18191,0)
 ;;=I12.9^^61^806^4
 ;;^UTILITY(U,$J,358.3,18191,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18191,1,3,0)
 ;;=3^Hypertensive CKD w/ Stage 1-4 CKD
 ;;^UTILITY(U,$J,358.3,18191,1,4,0)
 ;;=4^I12.9
 ;;^UTILITY(U,$J,358.3,18191,2)
 ;;=^5007066
 ;;^UTILITY(U,$J,358.3,18192,0)
 ;;=I13.0^^61^806^8
 ;;^UTILITY(U,$J,358.3,18192,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18192,1,3,0)
 ;;=3^Hypertensive HRT & CKD w/ Hrt Fail & Stg 1-4 CKD
 ;;^UTILITY(U,$J,358.3,18192,1,4,0)
 ;;=4^I13.0
 ;;^UTILITY(U,$J,358.3,18192,2)
 ;;=^5007067
 ;;^UTILITY(U,$J,358.3,18193,0)
 ;;=I13.10^^61^806^10
 ;;^UTILITY(U,$J,358.3,18193,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18193,1,3,0)
 ;;=3^Hypertensive HRT & CKD w/o Hrt Fail & Stg 1-4 CKD
 ;;^UTILITY(U,$J,358.3,18193,1,4,0)
 ;;=4^I13.10
 ;;^UTILITY(U,$J,358.3,18193,2)
 ;;=^5007068
 ;;^UTILITY(U,$J,358.3,18194,0)
 ;;=I13.11^^61^806^11
 ;;^UTILITY(U,$J,358.3,18194,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18194,1,3,0)
 ;;=3^Hypertensive HRT & CKD w/o Hrt Fail & Stg 5 CKD/ESRD
 ;;^UTILITY(U,$J,358.3,18194,1,4,0)
 ;;=4^I13.11
 ;;^UTILITY(U,$J,358.3,18194,2)
 ;;=^5007069
 ;;^UTILITY(U,$J,358.3,18195,0)
 ;;=I13.2^^61^806^9
 ;;^UTILITY(U,$J,358.3,18195,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18195,1,3,0)
 ;;=3^Hypertensive HRT & CKD w/ Hrt Fail & Stg 5 CKD/ESRD
 ;;^UTILITY(U,$J,358.3,18195,1,4,0)
 ;;=4^I13.2
 ;;^UTILITY(U,$J,358.3,18195,2)
 ;;=^5007070
 ;;^UTILITY(U,$J,358.3,18196,0)
 ;;=I15.0^^61^806^15
 ;;^UTILITY(U,$J,358.3,18196,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18196,1,3,0)
 ;;=3^Renovascular Hypertension
 ;;^UTILITY(U,$J,358.3,18196,1,4,0)
 ;;=4^I15.0
 ;;^UTILITY(U,$J,358.3,18196,2)
 ;;=^5007071
 ;;^UTILITY(U,$J,358.3,18197,0)
 ;;=I15.1^^61^806^3
